Sano Y, Ksander B R, Streilein J W
Schepens Eye Research Institute, Boston, Massachusetts 02114, USA.
Invest Ophthalmol Vis Sci. 1995 Oct;36(11):2176-85.
Corneal allografts placed in human eyes at high risk often fail, and immune rejection is thought to be a major pathogenic factor. To understand the immunologic factors responsible for rejection in this instance, the authors have created "high-risk" eyes in mice by inducing corneal neovascularization. The authors then examined the fate of orthotopic corneal grafts placed in these beds and assessed the development of donor-specific delayed hypersensitivity (DH) in recipient mice.
Three interrupted sutures were placed in the central cornea of recipient BALB/c mice to induce corneal neovascularization. Two weeks later, when corneal vessels occupied more than two quadrants of the cornea, mice received orthotopic corneal grafts from donor mice expressing alloantigens encoded by major and minor histocompatibility loci. Corneal allografts were evaluated by slit-lamp examination after grafting, and recipient mice were examined at the time of the rejection to determine whether they had acquired DH to alloantigens expressed on the corneal grafts.
Compared to grafts placed in normal eyes, a much higher incidence of rejection was observed among corneal allografts placed in neovascularized eyes (96.7% versus 46.7%). Moreover, grafts in neovascularized beds were rejected much more swiftly (2 weeks versus > 3 to 4 weeks). Rejection of corneal allografts in high-risk eyes coincided temporally with development of intense donor-specific DH, and the specificity of this immune response was directed solely at minor H antigens (not major histocompatibility complex-encoded antigens) on the graft.
These results indicate that eyes rendered high risk by virtue of corneal neovascularization fail to provide immune privilege for orthotopic corneal allografts. In this circumstance, the grafts rapidly induce intense donor-specific DH that is readily detectable within 2 weeks of engraftment, at which time the grafts are acutely and universally rejected. The recipient DH response is directed exclusively at minor H antigens on the graft, which is consistent with the view that neovascularization creates graft beds in which recipient antigen-presenting cells infiltrate the graft and carry antigenic information by lymphatics to draining lymph nodes. In this manner, anterior chamber-associated immune deviation is avoided, and potentially allodestructive DH is promoted.
置于高危人眼中的同种异体角膜移植常常失败,免疫排斥被认为是主要致病因素。为了解这种情况下导致排斥的免疫因素,作者通过诱导角膜新生血管形成在小鼠中创建了“高危”眼。然后作者检查了置于这些眼床中的原位角膜移植的转归,并评估了受体小鼠中供体特异性迟发型超敏反应(DH)的发展情况。
在受体BALB/c小鼠的中央角膜放置3根间断缝线以诱导角膜新生血管形成。两周后,当角膜血管占据角膜的两个以上象限,小鼠接受来自表达由主要和次要组织相容性位点编码的同种异体抗原的供体小鼠的原位角膜移植。移植后通过裂隙灯检查评估角膜同种异体移植,在排斥发生时检查受体小鼠,以确定它们是否已获得针对角膜移植上表达的同种异体抗原的DH。
与置于正常眼中的移植相比,置于新生血管化眼中的角膜同种异体移植排斥发生率更高(96.7%对46.7%)。此外,新生血管化眼床中的移植排斥更快(2周对>3至4周)。高危眼中角膜同种异体移植的排斥在时间上与强烈的供体特异性DH的发展一致,并且这种免疫反应的特异性仅针对移植上的次要组织相容性抗原(而非主要组织相容性复合体编码的抗原)。
这些结果表明,因角膜新生血管形成而处于高危状态的眼不能为原位角膜同种异体移植提供免疫赦免。在这种情况下,移植迅速诱导强烈的供体特异性DH,在植入后2周内即可轻易检测到,此时移植被急性且普遍地排斥。受体DH反应仅针对移植上的次要组织相容性抗原,这与新生血管形成创建移植床的观点一致,在移植床中受体抗原呈递细胞浸润移植并通过淋巴管将抗原信息携带至引流淋巴结。通过这种方式,避免了前房相关免疫偏离,并促进了潜在的同种异体破坏性DH。